A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Budesonide MMX 9 mg Extended-release Tablets as Add-on Therapy in Patients with Active, Mild or Moderate Ulcerative Colitis not Adequately Controlled on a Background Oral 5-ASA Regimen

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Budesonide MMX 9 mg Extended-release Tablets as Add-on Therapy in Patients with Active, Mild or Moderate Ulcerative Colitis not Adequately Controlled on a Background Oral 5-ASA Regimen

Completed
Phase of Trial: Phase III

Latest Information Update: 18 May 2017

At a glance

  • Drugs Budesonide (Primary)
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Acronyms CONTRIBUTE
  • Sponsors Salix Pharmaceuticals; Santarus; Valeant Pharmaceuticals International
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 May 2017 According to a Salix Pharmaceuticals media release, the study was published in the Journal of Crohn's & Colitis.
    • 20 Feb 2015 Data from this study were presented at the 10th Congress of the European Crohn's and Colitis Organisation (ECCO), according to a Ferring Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top